<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="196303">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00535639</url>
  </required_header>
  <id_info>
    <org_study_id>TT-01</org_study_id>
    <nct_id>NCT00535639</nct_id>
  </id_info>
  <brief_title>Tolerability of ALK Tree Tablet</brief_title>
  <official_title>A Randomised, Multiple Dose, Dose Escalation, Double-Blind, Placebo-Controlled Phase I Study Investigating the Safety of ALK Tree Tablet in Adult Subjects With Birch Pollen Induced Rhinoconjunctivitis (With/Without Asthma).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <brief_summary>
    <textblock>
      This trial is performed to assess the tolerability of the ALK Tree Tablet in patients with
      birch pollen induced allergy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double-Blind</masking>
  </study_design_info>
  <condition>Allergy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betula Verrucosa allergen extract</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical history of birch pollen induced rhinoconjunctivitis (with or without mild
             to moderate asthma ) of at least two years prior to trial entry requiring symptomatic
             treatment during the birch pollen season.

          -  Positive Skin Prick Test response to Betula verrucosa

          -  Positive specific IgE against Bet v1

          -  FEV1 ≥ 70% of predicted value

        Exclusion Criteria:

          -  No clinical history of perennial allergic rhinitis and/or asthma caused by an
             allergen to which the subject is regularly exposed and sensitised

          -  No clinical history of significant recurrent acute sinusitis (defined as 2 episodes
             per year for the last two years all of which required antibiotic treatment) or
             chronic sinusitis

          -  No conjunctivitis, rhinitis or asthma at the screening or randomisation visit

          -  No history of anaphylaxis, including anaphylactic food allergy, bee venom
             anaphylaxis, exercise anaphylaxis or drug induced anaphylaxis

          -  No history of angioedema
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Kim Krogsgaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PhaseOne Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PhaseOne Trials</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <lastchanged_date>February 28, 2008</lastchanged_date>
  <firstreceived_date>September 25, 2007</firstreceived_date>
  <keyword>Tolerability of ALK Tree Tablet in patients with birch pollen induced allergy</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
